Insmed Reports Positive Phase 3b ENCORE Data For ARIKAYCE; Stock Up In Pre-Market

Insmed Incorporated (INSM) on Monday reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE in patients with a new occurrence of Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics. Shares rose more than 10% in pre-market trading.The ENCORE trial assessed once-daily ARIKAYCE plus multidrug therapy versus placebo plus multidrug therapy over 12 months. Among participants, 82.4% were experiencing their first MAC infection, while 17.6% had ...